14 recruiting, 12 completed, 8 active not recruiting, 6 terminated. 27 Phase 2, 19 Phase 1, 6 Phase 3, 3 Not applicable, 1 Early Phase 1.
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Topotecan - usual, Topotecan - study - SCLC | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | 600 | 2026-10-05 | 2026-10-08 |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC HLX3901 - SCLC, NEC | Phase 1 | Recruiting | Shanghai Henlius Biotech | 138 | 2026-04-17 | 2026-07-08 |
| Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC golidocitinib with PD-1 inhibitors - SCLC, SCLC, Extensive Stage | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 20 | 2025-10-31 | 2026-02-27 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity - SCLC | Phase 2 | Not yet recruiting | The Second Affiliated Hospital of Dalian Medical University | 40 | 2025-02-28 | 2025-02-11 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors TUB-030 - Advanced Solid Tumors, HNSCC | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 250 | 2024-12-13 | 2026-09-11 |
| PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer PM8002, Paclitaxel, Topotecan - SCLC | Phase 3 | Active not recruiting | Biotheus Inc. | 404 | 2024-11-13 | 2026-10-22 |
| Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study Mirabegron - NSCLC, SCLC | Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 260 | 2024-07-15 | 2024-08-02 |
| Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell Toripalimab plus Anlotinib, Toripalimab - SCLC, Maintenance Treatment | Phase 3 | Not yet recruiting | Taizhou Hospital | 136 | 2024-07-01 | 2024-06-04 |
| Adebrelimab + Apatinib in SCLC Maintenance Therapy Adebrelimab combined with Apatinib - SCLC | Phase 2 | Recruiting | Tang-Du Hospital | 60 | 2024-06-20 | 2024-06-26 |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer ZL-1310, Atezolizumab, Carboplatin - SCLC | Phase 1 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 339 | 2024-01-23 | 2026-10-16 |
| Cognitive Screening in Lung Cancer Patients Lung Disease, NSCLC (Non-small Cell Lung Cancer) | Recruiting | European Institute of Oncology | 200 | 2024-01-10 | 2024-12-10 | |
| Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS) Online adaptive radiation therapy - Prostate Cancer, Head and Neck Cancer | Recruiting | Charite University, Berlin, Germany | 649 | 2023-10-11 | 2023-11-03 | |
| MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer Durvalumab, Monalizumab, Carboplatin or Cisplatin - Small Cell Lung Cancer, SCLC | Phase 2 | Recruiting | Hirva Mamdani | 84 | 2023-09-26 | 2026-04-29 |
| TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Palbociclib Oral Product, TAS-116 - Advanced Breast Cancer, Treatment-Refractory Solid Tumors | Phase 1 | Withdrawn | Brown University | 2023-09-12 | 2024-09-19 | |
| Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection SCLC | Recruiting | Boryung Pharmaceutical Co., Ltd | 300 | 2023-08-16 | 2025-09-16 | |
| Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS) - NSCLC, Renal Cell Carcinoma | Not applicable | Active not recruiting | Wake Forest University Health Sciences | 58 | 2023-07-11 | 2026-04-06 |
| A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC PM8002, Platinum, Etoposide - SCLC | Phase 2 | Active not recruiting | Biotheus Inc. | 50 | 2023-06-01 | 2025-03-12 |
| GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi) - SCLC, Malignant Melanoma | Phase 1 | Terminated | Y-mAbs Therapeutics | 23 | 2022-11-17 | 2026-06-18 |
Showing 20 of 48. Sign in to see all of them.
Small Cell Lung Carcinoma (16) · Lung Neoplasms (8) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Ovarian Neoplasms (4) · Carcinoma, Small Cell (3) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Head and Neck Neoplasms (3) · Melanoma (3) · Prostatic Neoplasms (3) · Sarcoma (3) · Triple Negative Breast Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2)
Neoplasms by Site (27) · Neoplasms (25) · Respiratory Tract Diseases (19) · Respiratory Tract Neoplasms (19) · Thoracic Neoplasms (19) · Lung Diseases (18) · Bronchial Neoplasms (16) · Carcinoma, Bronchogenic (16) · Neoplasms by Histologic Type (13) · Lung Neoplasms (11) · Neoplasms, Glandular and Epithelial (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Carcinoma (9) · Female Urogenital Diseases (9)
Carboplatin (5) · Etoposide (5) · Cisplatin (3) · PM 01183 (3) · pazopanib (3) · Paclitaxel (2) · anlotinib (2) · atezolizumab (2) · berzosertib (2) · durvalumab (2) · olaparib (2) · pembrolizumab (2) · Bevacizumab (1) · Drug Therapy (1) · E-3810 (1)
Biotheus Inc. (3) · National Cancer Institute (NCI) (2) · Samsung Medical Center (2) · Shanghai Chest Hospital (2) · Y-mAbs Therapeutics (2) · Astellas Pharma Inc (1) · AstraZeneca (1) · Boryung Pharmaceutical Co., Ltd (1) · Brown University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Charite University, Berlin, Germany (1) · Clovis Oncology, Inc. (1) · Daiichi Sankyo (1) · Dana-Farber Cancer Institute (1) · Eli Lilly and Company (1)
United States (23) · China (14) · France (6) · Germany (6) · South Korea (6) · Spain (6) · Italy (5) · United Kingdom (4) · Netherlands (3) · Australia (2) · Canada (2) · Greece (2) · Israel (2) · Switzerland (2) · Belgium (1)
Anish Thomas, M.D. (2) · Ying Cheng (2) · Baohui Han (1) · Caicun Zhou (1) · David Jackman, MD (1) · Dirk De Ruysscher, MD PhD (1) · Gabriella Pravettoni (1) · Gen Lin, MD,PhD (1) · Glenn Lesser, MD (1) · Haifeng Liu (1) · Hirva Mamdani, MD (1)
PMID 28581401, PMID 30012190, PMID 32238921, PMID 32771088, PMID 34187739, PMID 35756843, PMID 35844029, PMID 36116169, PMID 37491889, PMID 37939124, PMID 39173229, PMID 40543428, PMID 40932470, PMID 40963055, PMID 41740031, PMID 41791703, PMID 42081171
2015 (1), 5UG1CA189824-08 (1)